JP2012508737A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508737A5
JP2012508737A5 JP2011536316A JP2011536316A JP2012508737A5 JP 2012508737 A5 JP2012508737 A5 JP 2012508737A5 JP 2011536316 A JP2011536316 A JP 2011536316A JP 2011536316 A JP2011536316 A JP 2011536316A JP 2012508737 A5 JP2012508737 A5 JP 2012508737A5
Authority
JP
Japan
Prior art keywords
magl
pharmaceutical composition
compound
cells
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508737A (ja
JP5576874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/006045 external-priority patent/WO2010056309A2/en
Publication of JP2012508737A publication Critical patent/JP2012508737A/ja
Publication of JP2012508737A5 publication Critical patent/JP2012508737A5/ja
Application granted granted Critical
Publication of JP5576874B2 publication Critical patent/JP5576874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536316A 2008-11-14 2009-11-10 モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 Expired - Fee Related JP5576874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19928608P 2008-11-14 2008-11-14
US61/199,286 2008-11-14
PCT/US2009/006045 WO2010056309A2 (en) 2008-11-14 2009-11-10 Methods and compositions related to targeting monoacylglycerol lipase

Publications (3)

Publication Number Publication Date
JP2012508737A JP2012508737A (ja) 2012-04-12
JP2012508737A5 true JP2012508737A5 (cg-RX-API-DMAC10.html) 2012-12-13
JP5576874B2 JP5576874B2 (ja) 2014-08-20

Family

ID=42170582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536316A Expired - Fee Related JP5576874B2 (ja) 2008-11-14 2009-11-10 モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物

Country Status (6)

Country Link
US (1) US8772318B2 (cg-RX-API-DMAC10.html)
EP (1) EP2373315A4 (cg-RX-API-DMAC10.html)
JP (1) JP5576874B2 (cg-RX-API-DMAC10.html)
AU (1) AU2009314629B2 (cg-RX-API-DMAC10.html)
CA (1) CA2743861A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010056309A2 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
US9981972B2 (en) 2014-05-22 2018-05-29 Abide Therapeutics, Inc. N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
EP3331536A4 (en) * 2015-08-03 2019-03-27 The Regents of The University of California COMPOSITIONS AND METHODS OF MODULATING THE ABHD2 ACTIVITY
US10336709B2 (en) 2015-10-02 2019-07-02 Abide Therapeutics, Inc Lp-PLA2 inhibitors
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2017222713A1 (en) * 2016-06-24 2017-12-28 Indiana University Research & Technology Corporation A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX2019008626A (es) 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Magl阻害薬としての複素環式スピロ化合物
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
WO2019200224A1 (en) * 2018-04-13 2019-10-17 The Broad Institute, Inc. Synergistic drug combinations predicted from genomic features and single-agent response profiles
MA52635A (fr) 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CA3106510A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
US11147805B2 (en) 2019-02-07 2021-10-19 Medipure Pharmaceuticals Inc. Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
CN109750104A (zh) * 2019-03-18 2019-05-14 南通大学附属医院 Abhd6在非小细胞肺癌诊断、预后、治疗产品中的应用
CA3155260A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods for reducing rewarding effects of morphine without affecting its analgesic effects
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI924832B (zh) * 2021-04-01 2026-05-11 日商小野藥品工業股份有限公司 Abhd6拮抗劑
CN113527270B (zh) * 2021-07-16 2024-03-01 河南大学 一种靶向单酰基甘油脂肪酶的protac分子的医药中间体、制备方法及应用
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
JP7852604B2 (ja) * 2022-09-30 2026-04-28 小野薬品工業株式会社 Abhd6アンタゴニストを含有する医薬組成物
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499484A1 (en) * 2002-09-19 2004-04-01 Medigene Aktiengesellschaft Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
EP1817025A2 (en) * 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
US7989623B2 (en) * 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
AU2009330821B2 (en) 2008-12-24 2015-06-11 Bial - Portela & Ca, S.A. Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP5576874B2 (ja) モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
Jiang et al. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence
Wan et al. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456
Cao et al. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
Decker et al. EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides
Chang et al. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis
US9289415B2 (en) Treatment of cancer
Checa et al. Circulating levels of sphingosine-1-phosphate are elevated in severe, but not mild psoriasis and are unresponsive to anti-TNF-α treatment
Meel et al. MELK inhibition in diffuse intrinsic pontine glioma
Li et al. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors
Undevia et al. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R (+) XK469 in patients with advanced solid tumours
US20230035892A1 (en) Methods and compositions for treating cancer
US9493813B2 (en) Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
Hernández-Corbacho et al. A novel role for DGATs in cancer
Zhang et al. Structure-based design of a selective class I histone deacetylase (HDAC) near-infrared (NIR) probe for epigenetic regulation detection in triple-negative breast cancer (TNBC)
Tng et al. Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation
KR20190090824A (ko) 암을 치료하는 방법
Gowda et al. Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport
Han et al. Cardiomyocyte OTUD1 drives diabetic cardiomyopathy via directly deubiquitinating AMPKα2 and inducing mitochondrial dysfunction
JP2024515885A (ja) パーキンソン病を処置及びモニタリングするための方法
Fan et al. Phosphodiesterase 4D promotes angiotensin II-induced hypertension in mice via smooth muscle cell contraction
Pergande et al. Mass spectrometry-based multiomics identifies metabolic signatures of sarcopenia in rhesus monkey skeletal muscle
JP2007522107A (ja) 心血管疾患の治療としての5−ht2受容体の調節方法
Pinto et al. Epigenetic changes in shear‐stressed endothelial cells
US20220288004A1 (en) Treatment and prevention of aging related-disease and/or aging by the inhibition of sphingolipids